BridgeBio Pharma, Inc. (BBIO) intrinsic value & 10-year financials
BridgeBio Pharma, Inc. (BBIO) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 52.1% a year to $502.1M, with an average return on invested capital of 178.0%.
- Graham intrinsic value
- —
- Share price (Oct 20, 2026)
- $67.94
- Market cap
- $13.0B
- Revenue (FY2025)
- $502.1M
- Revenue growth (10-yr CAGR)
- 52.1%
- ROIC (10-yr avg)
- 178.0%
- Free cash flow (FY2025)
- -$447.0M
BBIO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $502.1M | -$732.9M | -$3.78 | -$447.0M | -104.2% | 44.5% |
| FY2024 | $221.9M | -$543.3M | -$2.88 | -$521.7M | -267.2% | 39.8% |
| FY2023 | $9.3M | -$653.3M | -$3.95 | -$529.0M | -6528.8% | 49.3% |
| FY2022 | $77.6M | -$484.7M | -$3.26 | -$424.3M | -659.6% | 51.1% |
| FY2021 | $69.7M | -$586.5M | -$3.90 | -$511.2M | -827.1% | 117.0% |
| FY2020 | $8.2M | -$505.5M | -$3.80 | -$407.2M | -5752.0% | 1960.2% |
| FY2019 | $40.6M | -$288.6M | — | -$256.2M | -656.4% | -827.2% |
| FY2018 | — | -$169.5M | — | -$138.8M | — | 254.0% |
| FY2017 | — | -$43.8M | — | -$41.0M | — | -87.0% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BridgeBio Pharma, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
BridgeBio Pharma, Inc. has earned high returns on invested capital, averaging 25.4% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
BridgeBio Pharma, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, BridgeBio Pharma, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-125.56 per share.